Neovacs SA (FR:ALNEV) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Neovacs SA has announced a €0.2 million capital increase through the issuance of OCEANE-BSA securities, with the funds aimed at financing their Kinoïde® allergy research program and other promising Biotech and Medtech projects. This operation has already raised €24.7 million, resulting in significant share dilution, and the latest issuance could lead to the creation of additional new shares. Investors are warned of potential risks including market pressure on share prices and the dilutive impact of these financing operations.
For further insights into FR:ALNEV stock, check out TipRanks’ Stock Analysis page.